Towards Healthcare Research & Consulting
US Cell and Gene Therapy Market
Updated Date: 21 July 2026   |   Report Code: 6852

US Cell and Gene Therapy Market Demand, Size, and Growth Rate Forecast 2035

According to Payal Rabde, who specializes in the development and commercialization of CAR-T cell therapies and gene editing technologies, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. cell and gene therapy market. The global U.S. cell and gene therapy market size was estimated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.74 billion in 2026 to approximately USD 20 billion by 2035, expanding at a CAGR of 17.2% from 2026 to 2035. Her analysis highlights the increasing adoption of personalized cell and gene therapies, CAR-T cell therapies, gene editing technologies, viral and non-viral gene delivery systems, automated cell manufacturing platforms, and regenerative medicine approaches. The research also examines the competitive strategies of key industry participants, including, Novartis AG, Bristol Myers Squibb, Bluebird Bio, Sarepta Therapeutics, BioMarin Pharamceutical, Beam Therapeutics, and Editas Medicine, shaping the future by expanding allogenic cell therapy platforms, integrating AI-driven therapy design and manufacturing, strengthening scalable and automated bioprocessing, accelerating in vivo gene delivery innovation and broadening regenerative medicine application in the global U.S. cell and gene therapy market.

Last Updated : 21 July 2026 Category: Therapeutic Area Insight Code: 6852 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Epidemiology-Based Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Disease Burden Analysis
    • Total Population Analysis, By Region & Country
    • Disease Incidence Rate (New Cases)
    • Disease Prevalence (Existing Cases)
    • Mortality & Survival Rates
  • Patient Journey & Treatment Funnel Analysis
    • Patient Funnel Breakdown
    • Treatment Dynamics
    • Treatment Landscape & Clinical Pathway
  • Scenario Analysis (Base / Optimistic / Pessimistic)
  • Risk Assessment & Sensitivity Analysis
  • Opportunity Analysis, By Region
  • Regulatory Analysis
  • Pricing, Reimbursement & Access Analysis
    • Price Analysis, By Product Type, 2022-2035
    • Price Analysis, By Region, 2022-2035
    • Price Analysis, By Countries, 2022-2035
    • Impact of Price Analysis on Market
    • Reimbursement Landscape
    • Patient Economics
  • Trade Analysis
    • Import Analysis, 2022-2025
    • Export Analysis, 2022-2025
    • Key Tariff Rates
    • Key Trade Regulations Across Countries
  • Bill of Material Analysis
  • Technology & Innovation Landscape
    • Pipeline Analysis
    • Emerging Technologies
    • Patent Analysis
    • Product Lifecycle Analysis
    • Technology Adoption Trends
  • Sustainability & ESG Insights
  • Business Models
  • Investment & Funding Landscape
  • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • Global U.S. Cell and Gene Therapy Market Analysis, By Therapy Type
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Cell and Gene Therapy Market Analysis, By Indication/Therapeutic Area
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Cell and Gene Therapy Market Analysis, By Vectors Type
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Cell and Gene Therapy Market Analysis, By Manufacturing Type
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Cell and Gene Therapy Market Analysis, By End Use
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Cell and Gene Therapy Market Analysis, By Region
    • Market Size, Forecast & CAGR, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By Indication/Therapeutic Area, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By Vectors Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By Manufacturing Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By End Use, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Cell and Gene Therapy Market Analysis, By Country, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
      • U.S. U.S. Cell and Gene Therapy Market Analysis
    • U.S. U.S. Cell and Gene Therapy Market Analysis, By Therapy Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Cell and Gene Therapy Market Analysis, By Indication/Therapeutic Area, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Cell and Gene Therapy Market Analysis, By Vectors Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Cell and Gene Therapy Market Analysis, By Manufacturing Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Cell and Gene Therapy Market Analysis, By End Use, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Therapy Type
      • By Indication/Therapeutic Area
      • By Vectors Type
      • By Manufacturing Type
      • By End Use
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • Alnylam Pharmaceuticals Inc.
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Product Portfolio
          • Manufacturing Footprint
            • Plant Locations
            • Plant Capacity
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Product
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • Amgen Inc.
    • Biogen Inc
    • Dendreon Pharmaceuticals LLC.
    • Helixmith Co. Ltd.

FAQ's

Answer : The U.S. cell and gene therapy market stands at USD 4.74 billion in 2026 and is expected to reach USD 20 billion by 2035, growing at a CAGR of 17.2% from 2026 to 2035.

Answer : The U.S. cell and gene therapy market includes 5 segments by Therapy type, by Indication-Therapeutic Area, by Vector Type, by end use, and by Manufacturing Type.

Answer : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB.

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar